Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1073-1080

  Shin, Sang Joon ^a   Jeong, Jae Heon ^a   Park, Young Suk ^b   Lee, Kyung Hee ^c   Shim, Byoung Yong ^d   Kim, Tae Won ^e   Oh, Do Youn ^f   Lee, Myung Ah ^g   Kim, Yong Tai ^h   Kim, Yeul Hong ⁱ   Zang, Dae Young ^j   Roh, Jae Kyung ^a   Ahn, Joong Bae ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Asan Medical Center   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h National Health Insurance Corporation   (South Korea)

ⁱ College of Medicine   (South Korea)

^j Hallym University   (South Korea)

more..

Author keywords

Colorectal cancer; Elderly; Frail; S 1

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC ANTIMETABOLITE; OTERACIL; TEGAFUR;

ABDOMINAL PAIN; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COMORBIDITY; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPEPSIA; ELDERLY CARE; FATIGUE; FEMALE; FRAIL ELDERLY; FUNCTIONAL STATUS; HAND FOOT SYNDROME; HUMAN; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SKIN PIGMENTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; COLORECTAL TUMOR; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; OXONIC ACID; TEGAFUR;

EID: 84856076344     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9418-2     Document Type: Article

References (36)

1. Ries L, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner JM, Howelader N, Eisner MP, Reichman M, Edwards BK (eds) (2007) SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://see.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site
2. Yancik R, Ries LA (2004) Cancer in older persons: an international issue in an aging world. Semin Oncol 31(2):128-136
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905-914
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041-1047
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947
6. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136-147
7. Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345(2):145-146
8. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19(18):3801-3807
9. Daniele B, Simmonds PD, Best LY, Ross PJ, Cunningham D (1999) Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age? Eur J Cancer 35(12):1640-1649
10. Sundarajan V, Grann VR, Neugut AI (1999) Population based variation in the use of chemotherapy for colorectal cancer in the elderly. Proc Am Soc Clin Oncol 18413 (abst. 1598)
11. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15(9):1330-1338
12. Seymour M, Maughan T, Wasan H, Brewster A, Shepherd S, O'Mahoney M, May B, Thompson L, Meade A, Langley R (2007) Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. Proc Am Soc Clini Oncol 2518 S (abst. 9030)
13. Diaz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallen M, Marcuello E, Rifa J, Massuti T, Cervantes A, Anton A, Fernandez Martos C (1999) UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (Williston Park) 13(7 Suppl 3):35-40
14. Feliu J, Gonzalez Baron M, Espinosa E, Garcia Giron C, de la Gandara I, Espinosa J, Colmenarejo A, Jalon JI, Fernandez Y, de Castro J (1997) Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer 79(10):1884-1889
15. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097-4106
16. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8):2282-2292
17. Feliu J, Escudero P, Llosa F, Bolanos M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gomez L, Casado E, Gomez-Reina MJ, Gonzalez-Baron M (2005) Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 23(13):3104-3111
18. Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P (2003) EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88(5):648-653
19. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100(11):2355-2361
20. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83(2):141-145
21. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB (2006) A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan-and oxaliplatin-containing regimens. Br J Cancer 95(12):1637-1641
22. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC (2007) Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 12(5):543-554
23. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC (2007) A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 97(4):458-463
24. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23(20):4553-4560
25. Goldberg RM (2006) Therapy for metastatic colorectal cancer. Oncologist 11(9):981-987
26. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1):38-50
27. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370(9582):135-142
28. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582):143-152
29. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M (2006) XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94(7):969-975
30. Hochster HS, Luo W, Popa EC, Lyman BT, Mulcahy M, Beatty PA, Benson AB (2007) Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 25(34):5397-5402
31. Au HJ, Mulder KE, Fields AL (2003) Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 3(3):165-171
32. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24(25):4085-4091
33. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75(1):11-17
34. Yen-Revollo JL, Goldberg RM, McLeod HL (2008) Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 14(1):8-13
35. Jacobson S, Cha S, Sargent D, O'Connell M, Poon M, Buroker T, Kugler J, Goldberg R (2001) Tolerability, dose intensity, and benefit of 5FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) Study. Proc Am Soc Clini Oncol 20 (abstr 1534)
36. Goldberg R, Kohne C, Seymour M, de gramont A, Porschen R, Saltz L, Rougier P, Touornigand C, Grothey A, Sargent D (2007) A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6, 286 patients (pts) with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2518 S (abst 4011)